

# Yoh Watanabe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7894474/publications.pdf>

Version: 2024-02-01

18  
papers

273  
citations

1307594

7  
h-index

996975

15  
g-index

19  
all docs

19  
docs citations

19  
times ranked

485  
citing authors

#	ARTICLE	IF	CITATIONS
1	The first Japanese nationwide multicenter study of <i>BRCA</i> mutation testing in ovarian cancer: CHARacterizing the cross-sectional approach to Ovarian cancer geneTic TEsting of <i>BRCA</i> (CHARLOTTE). International Journal of Gynecological Cancer, 2019, 29, 1043-1049.	2.5	80
2	Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression. JAMA Oncology, 2019, 5, 833.	7.1	45
3	Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. International Journal of Clinical Oncology, 2016, 21, 168-176.	2.2	42
4	Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IBâ€“IIB cervical cancer. Journal of Gynecologic Oncology, 2018, 29, e11.	2.2	34
5	Diagnostic value of combination serum assay of lactate dehydrogenase, Dâ€“dimer, and Câ€“reactive protein for uterine leiomyosarcoma. Journal of Obstetrics and Gynaecology Research, 2019, 45, 189-194.	1.3	19
6	Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. Gynecologic Oncology, 2016, 141, 447-453.	1.4	16
7	Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2). PLoS ONE, 2021, 16, e0236907.	2.5	7
8	Association of g BRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study. Cancer Science, 2020, 111, 3350-3358.	3.9	7
9	Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial. Gynecologic Oncology, 2019, 155, 413-419.	1.4	6
10	Clinicopathologic features and<i>BRCA</i> mutations in primary fallopian tube cancer in Japanese women. Japanese Journal of Clinical Oncology, 2018, 48, 794-798.	1.3	5
11	MicroRNA Let-7c Contributes to Paclitaxel Resistance via Aurora-B in Endometrial Serous Carcinoma. Tohoku Journal of Experimental Medicine, 2020, 251, 263-272.	1.2	4
12	Primary osteosarcoma of the uterine cervix: A case report. Journal of Obstetrics and Gynaecology Research, 2017, 43, 1781-1783.	1.3	3
13	Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey. International Journal of Clinical Oncology, 2017, 22, 541-547.	2.2	2
14	The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer. International Journal of Clinical Oncology, 2021, 26, 2123-2129.	2.2	1
15	Optimal debulking surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.. Journal of Clinical Oncology, 2015, 33, 5591-5591.	1.6	1
16	MicroRNA-152 Regulates Endometrial Serous Carcinoma Cell Motility by Suppressing Matrix Metalloproteinase 10 Expression. Tohoku Journal of Experimental Medicine, 2022, 256, 249-258.	1.2	1
17	Abdominal Total Hysterectomy: The Modified Aldridge's Procedure with Noda's Method. The Surgery Journal, 2019, 05, S22-S26.	0.7	0
18	Laparoscopic surgery for subserosal leiomyoma torsion in the acute and chronic phases: A report of three cases. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2019, 35, 123-130.	0.0	0